ASCO® 2023 Insights: "Discussion of LBA4619, Phase 3 THOR Study - Results of Erdafitinib vs. Chemo in Advanced/Metastatic UC With Select FGFR Alterations (The Emerging Role of Targeted Therapy)"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Daniel Petrylak
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Daniel Petrylak
Login to view comments.
Click here to Login